Phase 2 N=62 Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)
Ovarian Cancer
Primary: PFS — 29.8 Months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=56 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
Brenner Tumor · Fallopian Tube Cancer · Ovarian Clear Cell Cystadenocarcinoma
Primary: Pathologic Complete Response Rates — 8 participants
Phase 2 N=28 Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma
Primary Peritoneal Carcinoma · Ovarian Carcinoma · Fallopian Tube Carcinoma
Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants
Phase 2 N=38 Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma
Ovarian Carcinoma · Primary Peritoneal Carcinoma
Primary: Progression-free Survival (PFS) — 56 percentage of participants
Phase 3 N=484 A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma
Ovarian Cancer
Primary: Progression Free Survival (PFS) as Determined by the Investigator, Per Response Evaluation Criteria for Solid Tumors (RECIST) — 12.4; 8.4 Months — p=<0.0001
Phase 2 N=32 Neoadjuvant Therapy for Ovarian Cancer
Epithelial Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancer
Primary: Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab — 7 protocol defined adverse events
Phase 2 N=45 Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma
Fallopian Tube Cancer · Ovarian Cancer · Malignant Tumor of Peritoneum
Primary: Six Month Progression Free Survival (PFS) — 43.9 percentage of participants
Phase 2 N=30 Papillary Serous Carcinoma of the Endometrium
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Phase 3 N=1,301 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms
Primary: Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population…
Phase 1 N=9 Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian
Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancer
Primary: Tolerated Dose — 80 mg/m^2
Phase 1 N=24 Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
Carcinosarcoma, Ovarian
Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients
Phase 2 N=59 Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Consolidation Progression-Free Survival — 13.3; 18.9 months
Phase 2 N=29 Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer
Ovarian Cancer
Primary: Progression Free Survival (PFS) of Combination Platinum Based Therapy With Anti-Programmed Death (PD)-1 Therapy Followed by Maintenance Anti-PD-1 Therapy in Patients…
Phase 2 N=1 Salvage Ovarian FANG™ Vaccine + Carboplatinum
Stage III Ovarian Cancer · Stage IV Ovarian Cancer
Primary: Time to Progression (TTP)
Phase 2 N=18 Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer
Ovarian Neoplasms Malignant (Excl Germ Cell) · Peritoneal Carcinoma · Fallopian Tube Cancer
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants
Phase 2 N=58 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Overall Survival — 32 months
Phase 2 N=23 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Recurrent Ovarian Cancer · Fallopian Tube Carcinoma · Primary Peritoneal Carcinoma
Primary: Progression-free Survival Rate After 6 Months of Treatment on Study — 0 participants
Phase 1 N=15 Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2
Phase 2 N=59 Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Number of Patients With Response — 9; 21; 24 Participants
Phase 3 N=831 An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy
Genital Neoplasms, Female · Fallopian Tube Neoplasms · Ovarian Neoplasms
Primary: Progression Free Survival (PFS) — 20.0; 22.2 Months — p=0.199
Phase 2 N=50 Gemcitabine in Ovarian Cancer
Ovarian Cancer
Primary: Best Overall Tumor Response — 6; 25; 10; 5 participants
Phase 2 N=45 Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Determine the Antitumor Activity of Gemcitabine/Carboplatin/Bevacizumab Regimen as Measured by the Probability of Surviving Progression-free for at Least 6 Months or…
Phase 1 N=6 A Trial Evaluating TG4050 in Ovarian Carcinoma.
Ovarian Carcinoma · Fallopian Tube Cancer · Peritoneal Carcinoma
Primary: Safety and Tolerability (Adverse Event Reported Per CTCAE v5) — 6; 0; 6; 6 Participants
Phase 2 N=122 European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Carcinoma
Primary: Progression-free Survival — 8.85; 8.32 months
Phase 2 N=16 Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer
Ovarian Cancer
Primary: Response Rate — 0; 1; 8; 6 Participants
Phase 2 N=86 Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer
Ovarian Cancer · Primary Peritoneal Cancer
Primary: Phase 1 - Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Carboplatin
Phase 3 N=1,021 A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer
Ovarian Cancer
Primary: Percentage of Participants With at Least One Adverse Event (AE) — 97.8 percentage of participants
Phase 2 N=85 Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
Ovarian Cancer
Primary: 2-year Progression-free Survival — 40; 40 percentage of participants
Phase 2 N=24 Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer
Ovarian Cancer Stage IIIC · Ovarian Cancer Stage IV
Primary: Best Overall Response and Objective Response Rate Following Treatment With CS-1008 in Combination With Chemotherapy (Paclitaxel/Carboplatin) in Locally Advanced or…
Phase 2 N=55 Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
Ovarian Neoplasm · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Clinical Response Rate. — 0; 19; 21; 60 percentage of participants